Borchardt J, Kirsten D, Jörres R, Kroeger C, Magnussen H
Krankenhaus Grosshansdorf, Zentrum für Pneumologie und Thoraxchirurgie.
Pneumologie. 1996 Jan;50(1):28-35.
For the past decade, there have been no data on the time course of drug-resistant tuberculosis and on risk factors for drug resistance in former West Germany. We reviewed the medical records of all patients with positive cultures for Mycobacterium tuberculosis from 1984 until 1993 in a hospital near Hamburg. Drug-susceptibility testing was performed for isoniazid, rifampicin, ethambutol, and streptomycin, using the modified proportion method. Of 1,055 patient, 9.6% had isolates resistant to one or more drugs. Of the isolates, 5.8% showed resistance to isoniazid or rifampicin and 1.8% to both isoniazid and rifampicin. There was no significant change of the resistance rate during the study period. Twenty six percent of 89 patients from South America, Africa or Asia had isolates resistant to one or more drugs, compared with 7.6% of 799 patients born in Germany (odds ratio (OR) 4.2; 95% confidence interval (95% CI) 2.5-7.3). Among patients born in Germany, 32% of 101 patients with a history of prior antituberculosis drug therapy had resistant organisms, versus 4.2% of 698 patients without prior therapy (OR 10.7; 95% CI 6.1-18.7). Resistance orates for 35 patients, who had been treated within the last 5 yrs, and for 65 patients, who had been treated more than 5 yrs ago, were 57 and 17%, respectively (OR 6.6; 95% CI 2.9-16.6). Our results suggest that there is no increase in the proportion of drug-resistant tuberculosis in our hospital, and that patients with a recent history of antituberculosis drug therapy and patients from South America, Africa, or Asia are at high risk for drug resistance.
在过去十年中,前西德地区缺乏有关耐药结核病病程及耐药危险因素的数据。我们回顾了汉堡附近一家医院1984年至1993年间所有结核分枝杆菌培养阳性患者的病历。采用改良比例法对异烟肼、利福平、乙胺丁醇和链霉素进行药敏试验。在1055例患者中,9.6%的患者分离株对一种或多种药物耐药。其中,5.8%的分离株对异烟肼或利福平耐药,1.8%的分离株对异烟肼和利福平均耐药。研究期间耐药率无显著变化。来自南美洲、非洲或亚洲的89例患者中,26%的患者分离株对一种或多种药物耐药,而德国出生的799例患者中这一比例为7.6%(优势比(OR)4.2;95%置信区间(95%CI)2.5 - 7.3)。在德国出生的患者中,有过抗结核药物治疗史的101例患者中32%有耐药菌,而无既往治疗史的698例患者中这一比例为4.2%(OR 10.7;95%CI 6.1 - 18.7)。过去5年内接受治疗的35例患者和5年多以前接受治疗的65例患者的耐药率分别为57%和17%(OR 6.6;95%CI 2.9 - 16.6)。我们的结果表明,我院耐药结核病的比例没有增加,近期有抗结核药物治疗史的患者以及来自南美洲、非洲或亚洲的患者耐药风险较高。